Literature DB >> 2531758

Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome.

G Del Prete1, A Tiri, E Maggi, M De Carli, D Macchia, P Parronchi, M E Rossi, M C Pietrogrande, M Ricci, S Romagnani.   

Abstract

Circulating T cells from four patients with the hyper-IgE syndrome were found to produce significantly lower concentrations of interferon-gamma (IFN-gamma) in response to stimulation with phytohemagglutinin (PHA) than did T cells from eight age-matched healthy controls, three patients with atopic dermatitis and one patient with chronic granulomatous disease. A clonal analysis revealed that patients with hyper-IgE syndrome had markedly lower proportions of circulating T cells able to produce IFN-gamma and tumor necrosis factor-alpha (TNF-alpha) in comparison with controls. In contrast, the proportions of peripheral blood T cells able to produce IL-4 or IL-2 were not significantly different in patients and controls. All the four patients with hyper-IgE syndrome showed high proportions of circulating CD4+ helper T cells able to induce IgE synthesis in allogeneic B cells, as well. Such an activity for IgE synthesis appeared to be positively correlated with IL-4 production by T cells and inversely related to the ability of the same T cells to produce IFN-gamma. Since IFN-gamma exerts an inhibitory effect on the synthesis of IgE and both IFN-gamma and TNF-alpha play an important role in inflammatory reactions, we suggest that the defective production of IFN-gamma may be responsible for hyperproduction of IgE and the combined defect of IFN-gamma and TNF-alpha may contribute to the undue susceptibility to infections seen in patients with hyper-IgE syndrome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2531758      PMCID: PMC304061          DOI: 10.1172/JCI114368

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Abnormalities of in vitro immunoglobulin synthesis by peripheral blood lymphocytes from untreated patients with Hodgkin's disease.

Authors:  S Romagnani; G F Del Prete; E Maggi; G Bellesi; G Biti; P L Rossi Ferrini; M Ricci
Journal:  J Clin Invest       Date:  1983-05       Impact factor: 14.808

2.  Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin.

Authors:  D Pennica; G E Nedwin; J S Hayflick; P H Seeburg; R Derynck; M A Palladino; W J Kohr; B B Aggarwal; D V Goeddel
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

3.  Human T cell clones can induce in vitro IgE synthesis in normal B cells regardless of alloantigen recognition or specificity for peculiar antigens.

Authors:  G Del Prete; E Maggi; D Macchia; A Tiri; P Parronchi; M Ricci; S Romagnani
Journal:  Eur J Immunol       Date:  1986-12       Impact factor: 5.532

4.  Activation through CD3 molecule leads a number of human T cell clones to induce IgE synthesis in vitro by B cells from allergic and nonallergic individuals.

Authors:  S Romagnani; G Del Prete; E Maggi; M Ricci
Journal:  J Immunol       Date:  1987-03-15       Impact factor: 5.422

5.  A T cell activity that enhances polyclonal IgE production and its inhibition by interferon-gamma.

Authors:  R L Coffman; J Carty
Journal:  J Immunol       Date:  1986-02-01       Impact factor: 5.422

6.  Markedly elevated serum IgE levels following allogeneic and syngeneic bone marrow transplantation.

Authors:  O Ringdén; U Persson; S G Johansson; H Wilczek; G Gahrton; C G Groth; G Lundgren; B Lönnqvist; E Möller
Journal:  Blood       Date:  1983-06       Impact factor: 22.113

7.  Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity.

Authors:  C F Nathan; H W Murray; M E Wiebe; B Y Rubin
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

8.  Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity.

Authors:  P S Steeg; R N Moore; H M Johnson; J J Oppenheim
Journal:  J Exp Med       Date:  1982-12-01       Impact factor: 14.307

9.  Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses.

Authors:  J Y Djeu; N Stocks; K Zoon; G J Stanton; T Timonen; R B Herberman
Journal:  J Exp Med       Date:  1982-10-01       Impact factor: 14.307

10.  Immune interferon and leukocyte-conditioned medium induce normal and leukemic myeloid cells to differentiate along the monocytic pathway.

Authors:  B Perussia; E T Dayton; V Fanning; P Thiagarajan; J Hoxie; G Trinchieri
Journal:  J Exp Med       Date:  1983-12-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

2.  Chemiluminescent and flow cytometric analysis of gamma interferon preincubation on neonatal and adult rat polymorphonuclear leukocytes.

Authors:  R R Wittler; M M Lieberman; D D Paine; S L Muehlbauer; J E Lima; D M Sachanandani; C A Pinney
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

3.  Regulation of IgE and IgG4 synthesis in patients with hyper IgE syndrome.

Authors:  A Ishizaka; K Joh; R Shibata; Y Wagatsuma; M Nakanishi; K Tomizawa; K Kojima; E Kandil; Y Sakiyama; S Matsumoto
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

4.  Collaborative Interferon-γ and Interleukin-17 Signaling Protects the Oral Mucosa from Staphylococcus aureus.

Authors:  Jobert G Barin; Monica V Talor; Julie A Schaub; Nicola L Diny; Xuezhou Hou; Matthew Hoyer; Nathan K Archer; Elizabeth S Gebremariam; Meghan F Davis; Lloyd S Miller; Noel R Rose; Daniela Čiháková
Journal:  Am J Pathol       Date:  2016-07-26       Impact factor: 4.307

5.  No indication for a defect in toll-like receptor signaling in patients with hyper-IgE syndrome.

Authors:  E D Renner; I Pawlita; F Hoffmann; V Hornung; D Hartl; M Albert; A Jansson; S Endres; G Hartmann; B H Belohradsky; S Rothenfusser
Journal:  J Clin Immunol       Date:  2005-07       Impact factor: 8.317

Review 6.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

7.  Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls.

Authors:  M Imada; F E Simons; F T Jay; K T Hayglass
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

8.  Fc epsilon receptor II/CD23+ lymphocytes in atopic dermatitis. III. Aberrant control in the in vitro expression of Fc epsilon RII/CD23 on peripheral blood T cells in atopic dermatitis.

Authors:  T Sakamoto; F Nakayama; T Tamamori; M Takigawa
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

9.  Genetic origins of hyper-IgE syndrome.

Authors:  Yoshiyuki Minegishi; Hajime Karasuyama
Journal:  Curr Allergy Asthma Rep       Date:  2008-09       Impact factor: 4.806

Review 10.  The hyper-IgE syndromes.

Authors:  Alexandra F Freeman; Steven M Holland
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.